CA2905403A1 - Treatment for chemotherapy-induced cognitive impairment - Google Patents

Treatment for chemotherapy-induced cognitive impairment Download PDF

Info

Publication number
CA2905403A1
CA2905403A1 CA2905403A CA2905403A CA2905403A1 CA 2905403 A1 CA2905403 A1 CA 2905403A1 CA 2905403 A CA2905403 A CA 2905403A CA 2905403 A CA2905403 A CA 2905403A CA 2905403 A1 CA2905403 A1 CA 2905403A1
Authority
CA
Canada
Prior art keywords
chemotherapy
treatment
composition
cognitive impairment
induced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2905403A
Other languages
English (en)
French (fr)
Inventor
Hossein A. Ghanbari
Zhi-Gang Jiang
Original Assignee
Panacea Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Pharmaceuticals Inc filed Critical Panacea Pharmaceuticals Inc
Publication of CA2905403A1 publication Critical patent/CA2905403A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60T—VEHICLE BRAKE CONTROL SYSTEMS OR PARTS THEREOF; BRAKE CONTROL SYSTEMS OR PARTS THEREOF, IN GENERAL; ARRANGEMENT OF BRAKING ELEMENTS ON VEHICLES IN GENERAL; PORTABLE DEVICES FOR PREVENTING UNWANTED MOVEMENT OF VEHICLES; VEHICLE MODIFICATIONS TO FACILITATE COOLING OF BRAKES
    • B60T7/00—Brake-action initiating means
    • B60T7/02—Brake-action initiating means for personal initiation
    • B60T7/04—Brake-action initiating means for personal initiation foot actuated
    • B60T7/042—Brake-action initiating means for personal initiation foot actuated by electrical means, e.g. using travel or force sensors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60T—VEHICLE BRAKE CONTROL SYSTEMS OR PARTS THEREOF; BRAKE CONTROL SYSTEMS OR PARTS THEREOF, IN GENERAL; ARRANGEMENT OF BRAKING ELEMENTS ON VEHICLES IN GENERAL; PORTABLE DEVICES FOR PREVENTING UNWANTED MOVEMENT OF VEHICLES; VEHICLE MODIFICATIONS TO FACILITATE COOLING OF BRAKES
    • B60T13/00—Transmitting braking action from initiating means to ultimate brake actuator with power assistance or drive; Brake systems incorporating such transmitting means, e.g. air-pressure brake systems
    • B60T13/10—Transmitting braking action from initiating means to ultimate brake actuator with power assistance or drive; Brake systems incorporating such transmitting means, e.g. air-pressure brake systems with fluid assistance, drive, or release
    • B60T13/12—Transmitting braking action from initiating means to ultimate brake actuator with power assistance or drive; Brake systems incorporating such transmitting means, e.g. air-pressure brake systems with fluid assistance, drive, or release the fluid being liquid
    • B60T13/14—Transmitting braking action from initiating means to ultimate brake actuator with power assistance or drive; Brake systems incorporating such transmitting means, e.g. air-pressure brake systems with fluid assistance, drive, or release the fluid being liquid using accumulators or reservoirs fed by pumps
    • B60T13/142—Systems with master cylinder
    • B60T13/145—Master cylinder integrated or hydraulically coupled with booster
    • B60T13/146—Part of the system directly actuated by booster pressure
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60T—VEHICLE BRAKE CONTROL SYSTEMS OR PARTS THEREOF; BRAKE CONTROL SYSTEMS OR PARTS THEREOF, IN GENERAL; ARRANGEMENT OF BRAKING ELEMENTS ON VEHICLES IN GENERAL; PORTABLE DEVICES FOR PREVENTING UNWANTED MOVEMENT OF VEHICLES; VEHICLE MODIFICATIONS TO FACILITATE COOLING OF BRAKES
    • B60T13/00—Transmitting braking action from initiating means to ultimate brake actuator with power assistance or drive; Brake systems incorporating such transmitting means, e.g. air-pressure brake systems
    • B60T13/10—Transmitting braking action from initiating means to ultimate brake actuator with power assistance or drive; Brake systems incorporating such transmitting means, e.g. air-pressure brake systems with fluid assistance, drive, or release
    • B60T13/66—Electrical control in fluid-pressure brake systems
    • B60T13/662—Electrical control in fluid-pressure brake systems characterised by specified functions of the control system components
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60T—VEHICLE BRAKE CONTROL SYSTEMS OR PARTS THEREOF; BRAKE CONTROL SYSTEMS OR PARTS THEREOF, IN GENERAL; ARRANGEMENT OF BRAKING ELEMENTS ON VEHICLES IN GENERAL; PORTABLE DEVICES FOR PREVENTING UNWANTED MOVEMENT OF VEHICLES; VEHICLE MODIFICATIONS TO FACILITATE COOLING OF BRAKES
    • B60T13/00—Transmitting braking action from initiating means to ultimate brake actuator with power assistance or drive; Brake systems incorporating such transmitting means, e.g. air-pressure brake systems
    • B60T13/10—Transmitting braking action from initiating means to ultimate brake actuator with power assistance or drive; Brake systems incorporating such transmitting means, e.g. air-pressure brake systems with fluid assistance, drive, or release
    • B60T13/66—Electrical control in fluid-pressure brake systems
    • B60T13/68—Electrical control in fluid-pressure brake systems by electrically-controlled valves
    • B60T13/686—Electrical control in fluid-pressure brake systems by electrically-controlled valves in hydraulic systems or parts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mechanical Engineering (AREA)
  • Neurology (AREA)
  • Transportation (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
CA2905403A 2013-03-14 2014-03-14 Treatment for chemotherapy-induced cognitive impairment Abandoned CA2905403A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/803,482 2013-03-14
US13/803,482 US20140271812A1 (en) 2013-03-14 2013-03-14 Treatment for chemotherapy-induced cognitive impairment
PCT/US2014/028039 WO2014152864A1 (en) 2013-03-14 2014-03-14 Treatment for chemotherapy-induced cognitive impairment

Publications (1)

Publication Number Publication Date
CA2905403A1 true CA2905403A1 (en) 2014-09-25

Family

ID=51528048

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2905403A Abandoned CA2905403A1 (en) 2013-03-14 2014-03-14 Treatment for chemotherapy-induced cognitive impairment

Country Status (5)

Country Link
US (1) US20140271812A1 (enExample)
EP (1) EP2968319B1 (enExample)
JP (2) JP6293258B2 (enExample)
CA (1) CA2905403A1 (enExample)
WO (1) WO2014152864A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2984379C (en) * 2015-04-28 2024-06-11 Newsouth Innovations Pty Limited Targeting nad+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies, and inactivity
WO2019147839A1 (en) * 2018-01-24 2019-08-01 Sensei Biotherapeutics, Inc. Methods and compositions for preserving neurogenesis
WO2022138842A1 (ja) * 2020-12-24 2022-06-30 参天製薬株式会社 エピナスチン又はその塩と硫黄系抗酸化剤を含有する経皮投与用医薬組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447427A (en) 1979-01-04 1984-05-08 The United States Of America As Represented By The Secretary Of The Army Method for treating bacterial infections with 2-acetyl- and 2-propionylpyridine thiosemicarbazones
US5180831A (en) * 1990-08-10 1993-01-19 Georgia Tech Research Corporation Quaternary pyridinium compounds
US5281715A (en) * 1992-05-13 1994-01-25 Yale University 2-formylpyridine thiosemicarbazone compounds
US6114376A (en) * 1997-04-30 2000-09-05 Mcgill University Methods for using macrocyclic lactone compounds as multidrug resistance reversing agents in tumor and other cells
US5869676A (en) 1997-05-15 1999-02-09 Vion Pharmaceuticals, Inc. Process for the synthesis of ribonucleotide reductase inhibitors 3-AP and 3-AMP
US5767134A (en) 1997-05-15 1998-06-16 Vion Pharmaceuticals, Inc. Prodrug forms of ribonucleotide reductase inhibitors 3-AP and 3-AMP
JP2007527854A (ja) * 2003-05-01 2007-10-04 パナシア ファーマシューティカルズ インコーポレーテッド 虚血関連状態の治療方法
US20060194810A1 (en) 2004-04-30 2006-08-31 Bijan Almassian Methods of treating ischemic related conditions
US20070243132A1 (en) * 2005-12-22 2007-10-18 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
US20080039471A1 (en) * 2006-08-14 2008-02-14 Ghanbari Hossein A Composition and method to inhibit tissue plasminogen activator (tPA) - potentiated neurotoxicity
WO2008083491A1 (en) * 2007-01-11 2008-07-17 Critical Outcome Technologies Inc. Compounds and method for treatment of cancer
US20090286799A1 (en) * 2008-05-16 2009-11-19 Zhi-Gang Jiang Methods for the treatment of brain edema
US20100120763A1 (en) * 2008-11-07 2010-05-13 Wyeth Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases
WO2010066010A1 (en) * 2008-12-12 2010-06-17 The University Of Melbourne Process for the preparation of asymmetrical bis(thiosemicarbazones)
WO2012149267A1 (en) * 2011-04-27 2012-11-01 Yale University Drug therapy to inhibit chemotherapy-induced adverse effects and related pharmaceutical compositions, diagnostics, screening techniques and kits

Also Published As

Publication number Publication date
WO2014152864A1 (en) 2014-09-25
EP2968319A1 (en) 2016-01-20
US20140271812A1 (en) 2014-09-18
EP2968319A4 (en) 2016-10-19
JP2018062537A (ja) 2018-04-19
JP6293258B2 (ja) 2018-03-14
EP2968319B1 (en) 2020-01-08
JP2016513723A (ja) 2016-05-16

Similar Documents

Publication Publication Date Title
US6174875B1 (en) Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
TWI400080B (zh) 藥物於治療患有青光眼和其他退化性眼疾之人的視力喪失上之用途
WO2017167168A1 (en) Compositions containing tannic acids and uses thereof
US20110117186A1 (en) Intravenous infusion of curcumin and a calcium channel blocker
Yu et al. Epothilone B benefits nigral dopaminergic neurons by attenuating microglia activation in the 6-hydroxydopamine lesion mouse model of Parkinson’s disease
Lambuk et al. Nanoparticles for the treatment of glaucoma-associated neuroinflammation
Nuzzi et al. Glaucoma: biological trabecular and neuroretinal pathology with perspectives of therapy innovation and preventive diagnosis
US9717772B2 (en) Interval therapy for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases
US11975111B2 (en) Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
US20180207227A1 (en) Therapeutic and Neuroprotective Peptides
EP4340894A1 (en) Anti-oxidant containing particles and methods of use
EP2968319B1 (en) Treatment for chemotherapy-induced cognitive impairment
WO1999051223A1 (en) Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
EP2958568B1 (en) Phosphaplatins as neuroprotective agents
JP2018090647A (ja) 化学療法誘発末梢神経障害の処置
Samim et al. Pathophysiology and management approaches for parkinson’s disease
US10576069B2 (en) Treatment for chemotherapy-induced cognitive impairment
US20150110853A1 (en) Treatment of radical prostatectomy-induced erectile dysfunction
US20230132378A9 (en) Compositions and methods for treating hemorrhagic stroke
US20170189376A1 (en) Butyroyloxymethyl diethyl phosphate compounds and uses thereof
Sonawane et al. Emerging neuroprotective paradigms in glaucoma: Pharmacotherapy and technological insights
Balbi Group I metabotropic glutamatergic receptors regulating glutamate release and microglia phenotype in a murine model of amyotrophic lateral sclerosis
HK40043513A (en) Interval therapy for the treatment of eye diseases
Beller Glutamate Transporters Potential To Reduce Excitotoxicity in CNS Injury and Neurodegenerative Disease

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20200831